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Abstract
Mycobacterium leprae is a highly infectious and low pathogenic microorganism that is the
causal agent of leprosy. The differences in vulnerability to leprosy, the spectral immune
response, and the clinical manifestations of this disease are related to different genetic
backgrounds among individuals. In this sense, genetic variants, especially in genes related
to mycobacteria recognition and host immune response, may be key factors to explain
individual susceptibility and resistance to leprosy and their conditions. In this chapter,
studies regarding association of genetic variants in pattern-recognition receptors (PRRs)
and leprosy will be reviewed revealing the importance of molecules such as Toll-like
receptors (TLRs) and nucleotide-binding oligomerization domain-containing protein 2
(NOD2) in leprosy initiation and maintenance.
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1. Introduction
Leprosy is caused by Mycobacterium leprae, which is an intracellular bacterium with high
infectivity and low pathogenicity. It means that there are a large number of people exposed to
this pathogen; however, the majority of them are naturally resistant. On the other hand, some
people develop leprosy once challenged with M. leprae. The people who develop disease may
present different clinical forms of leprosy. Some of them develop a localized disease, named
tuberculoid leprosy, with a strong host response, which does not avoid development of nerve
injury and physical disabilities. Some patients develop a more severe form of leprosy, named
lepromatous leprosy, whereas other patients present intermediate and instable clinical forms
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(borderline tuberculoid, borderline borderline, and borderline lepromatous). Besides, there are
different levels of susceptibility to leprosy reactions. The differences among M. leprae strains
are not sufficient to explain this variable outcome of leprosy. There is a variable spectrum of
host immune response that depends on the genetic characteristics of the infected individual.
The immunological and genetic basis underlyingM. leprae infection remains largely unknown.
In this sense, several studies have been conducted aiming to explore the molecular basis of
leprosy, and they are mainly focused on aspects of host-pathogen interaction and modulation
of host immune response against M. leprae.
Recognition of M. leprae by the host innate immune system is the first step in dealing with the
invading bacteria and is crucial to initialize the adaptive immune response to infection. Micro-
organisms are recognized by host through germline-encoded pattern-recognition receptors
(PRRs). The PRRs are able to sense highly conserved motifs from the invading microorgan-
isms. These motifs are called pathogen-associated molecular patterns (PAMPs) [1].
One family of PRRs is the Toll-like receptors (TLRs) that are expressed on cell surface of
different cells from innate immune system or endocytic vesicle membrane [2]. These receptors
have an extracellular domain that recognizes different bacterial agonists. The activation of
TLRs mediate host immune response regulating phagocytosis and antimicrobial activity or
initiating signaling cascades (through activation of transcription factors NF-κB and IRF) cul-
minating in modulation of cytokines and chemokines release [3].
There is another family of PRR, called nucleotide-binding oligomerization domain (NOD)-like
receptors (NLRs) that are cytoplasmic receptors, and they are able to recognize bacterial agonists
inside the host cells. Some members of this family activates NF-κB, interferon regulatory factors
(IRFs), and mitogen-activated protein kinases (MAPKs), which control the expression of media-
tors of immune response, such as cytokines, chemokines, and type I interferons. On the other
hand, other members lead to activation of caspase-1 acting through inflammasomes [4].
Genetic variants leading to functional changes in PRRs, such as TLRs and NLRs, may be
involved with differences in host immune response modulation and consecutive susceptibility
or resistance to leprosy and their clinical forms as well leprosy reactions.
In this chapter, studies about genetic association of PRRs, specifically TLRs and NOD2, with
leprosy will be reviewed.
2. Genetic variations in toll-like receptors (TLRs)
TLRs were first described in the mid-1990s after genome sequencing of Drosophila melanogaster.
Toll protein from D. melanogaster was identified as an important molecule in initiating innate
immune response in this organism in response to fungal infection and Gram-positive bacteria.
This molecule was also described as important in embryonic dorsoventral patterning [5]. After
this first description, proteins similar to Toll protein from D. melanogaster were identified in
mammalian cells, including humans, and they are referred as Toll-like receptors. TLRs are
members of superfamily of interleukin receptors, and they act as PRRs recognizing PAMPs [6, 7].
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The TLRs are also type 1 transmembrane receptors and may be expressed at cell surface or
endocytic vesicle membrane. The receptors TLR1, TLR2, TLR4, TLR5, and TLR6 are expressed
at cell surface, whereas TLR7, TLR8, and TLR9 are expressed at endosomes and lysosomes.
TLR3 may be expressed either at cell surface and endosomes or lysosomes [2]. The intracellular
TLRs recognize viral and bacterial nucleic acids [8].
There are ten human TLRs already described (TLR1–TLR10), and they recognize different
kinds of ligands [2, 9]. TLR1, TLR2, and TLR6 are mainly stimulated by lipoproteins from
Gram-positive bacteria; TLR2 also recognizes lipoteichoic acid (Gram-positive bacteria),
zymosan, β-glucan from fungi, and GPI anchors; TLR3 recognizes dsRNA from viruses;
TLR4 is activated by lipopolysaccharides (Gram-negative bacteria) and GPI anchors; TLR5
recognizes bacterial flagellin; TLR7 and TLR8 recognize ssRNA from viruses; TLR9 is acti-
vated by DNA; and ligands for TLR10 are still not known [10]. TLRs are also able to sense
and signal tissue damage through recognition of damage-associated molecular pattern mol-
ecules (DAMPs) [11].
After recognition of ligands by the specific TLR, a dimerization of TLRs as homodimers or
heterodimers may occur. Ligation of TLR and a ligand may also lead to conformational
changes in dimers. The differential association in heterodimers causes a diversification in
ligand recognition. For example, the heterodimer TLR1-TLR2 recognizes triacylated bacterial
lipopeptides, whereas TLR2-TLR6 heterodimer recognizes diacylated lipopeptides [12, 13].
Dimerization and conformational changes will activate intracellular signaling cascade and
innate immune response against the pathogen, produce acute inflammation, lead to modula-
tion of adaptive immune response, and induce antimicrobial pathways [3, 12, 14].
The important roles played by TLR in recognizing PAMPs, especially PAMPs from M. leprae
and initiation of immune response, highlight its potential involvement with leprosy suscepti-
bility and development. In the following sections, studies about association between poly-
morphisms in TLR1, TLR2, and TLR4 leprosy will be presented. The genetic association
studies between TLRs and leprosy are summarized in Table 1. The other TLRs do not interact
with M. leprae or do not have genetic association with leprosy.
2.1. Genetic variations in TLR1
The heterodimer formed by TLR1 and TLR2 recognizes killed M. leprae through triacylated
lipoproteins leading to cell activation. These two receptors are expressed in a higher level in
localized tuberculoid form than in disseminated lepromatous form, evidencing the role of
TLRs in host defense. Type-1 cytokines IFN-γ, GM-CSF, IL-12, and IL-18 stimulate TLR1 and
TLR2 activation, while type-2 cytokines IL-4 and IL-10 impair its activation. Although TLR1
response is important to fight infection, exacerbated activation of TLR can lead to immunopa-
thology, tissue damage, and, in the case of leprosy, nerve damage [15].
The involvement of TLR1 in leprosy has been highlighted by several association studies.
Some polymorphisms in TLR1 were studied in different populations revealing their associa-
tion with conditions related to leprosy. One of them is the SNP rs5743618 (T/G I602S) which
presents a variable frequency depending on the population. Hawn et al. (2007) showed that
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Table 1. Association studies of genetic polymorphisms in TLRs and leprosy.
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rs5743618 in TLR1 is involved with the regulation of innate immune response to triacylated
lipopeptides (ligands of TLR1/TLR2 heterodimer), and it is also related to the differential
response to M. tuberculosis extract. The 602I variant was shown as able to induce an increased
level of NF-κB signaling after induction by lipopeptides in a Vietnamese population. As
expected, there is also an association with the cytokine profile as the 602I genotype presents a
higher production of IL-6 in whole blood stimulated with lipopeptides supporting the role of
TLR receptors in activating innate immune response against M. leprae [16]. In the same year,
Johnson and coll. (2007) noted an association of this same SNP rs5743618 with surface traffick-
ing of TLR1 and response of blood monocytes to bacterial ligands. More specifically, the
variant 602S is associated with an impairment of TLR1 expression in cell surface leading to a
loss of cellular responses. Corroborating these evidences, the variant 602S was shown to be a
protective factor for leprosy [17]. Wong and coll. (2010) have analyzed the data frommore than
1500 individuals from different studies and regions and identified TLR1 and HLA-DRB1DQA1
as the main genes related to leprosy susceptibility. Besides that, the protective variant 602S is
rare in Africa but is the most frequent among European descendants, which suggests the
selection pressure over this locus from mycobacteria [18].
Investigating the possible involvement of TLR1 with adaptive immune response affecting the
clinical manifestations of leprosy, Misch and coll. (2008) evaluated rs5743618 polymorphism
demonstrating a decrease of NF-κB activity related to the 1805G allele. In a Nepalese sample,
the 1805G allele was protective against reversal reaction, which is characterized by an exacer-
bated Th1 cytokine response [19]. Another polymorphism able to interfere with TLR1 activity
is rs4833095 (C/T N248S) as the 248 N variant impairs TLR1 functioning and sensing of
microbial cell wall components [20]. In a Bangladeshi study, the homozygous 248SS genotype
was associated with leprosy, but 248 N is homogeneously distributed among subjects. The
248 N allele is associated with erythema nodosum leprosum, while patients with reversal
reaction are more likely to have the 248S allele [21]. These results were corroborated in a
Brazilian sample, in which an association effect of 248S allele with leprosy susceptibility was
found. In this same study, no association was identified between rs5743618 and leprosy
diverging from previous results. However, rs4833095 was shown to be in a moderate linkage
disequilibrium with rs5743618, suggesting a higher effect of the last one among Brazilians. The
susceptibility allele 248S leads to a lower tumor necrosis factor (TNF)/IL-10 ratio after stimula-
tion with M. leprae, and this same allele influences on TLR1 structure which may explain the
functional alterations [22]. The association of 248S allele was not confirmed by Santana and
coll. (2017) in another study with a Brazilian sample. However, they found association of
rs4833095 with differential production of IL-17 and IL-12p40 [23]. These variations in TLR1
highlight the functional role of these genetic determinants in modulating the immune response
during M. leprae infection.
2.2. Genetic variations in TLR2
TLR2 can form heterodimer with TLR1, as mentioned before, and with TLR6. These differ-
ent forms of presentation allow TLR2 to recognize different cell wall components, such as
lipopeptides, peptidoglycan, glycosylphosphatidylinositol-linked proteins, and zymosan
[24].
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TLR2 is responsible by recognition of cell wall fractions from M. leprae and mediate
proinflammatory signaling by stimulating TNF-α production in macrophages in a Toll-like
receptor-dependent manner [25]. Moreover, TLR2 is able to stimulate NF-κB signaling and
subsequent induction of inflammatory cytokines [26]. As described to TLR1, type-1 cytokines
IFN-γ, GM-CSF, IL-12, and IL-18 lead to enhancement of TLR2 activation, and type-2 cyto-
kines IL-4 and IL-10 inhibit activation of TLR2 [15]. TLR2 is also expressed at surface of
Schwann cells. Recognition of lipoproteins from M. leprae by TLR2 is required to stimulate
apoptosis of these cells and may be related to nerve injury in leprosy [27].
In this way, variations in TLR2 could be associated with a differential response against
mycobacteria and be involved with individual susceptibility to leprosy. Looking for genetic
variants in TLR2 in an association study about leprosy, Kang and coll. (2001) performed a
screening in intracellular domain in leprosy patients. They detected the polymorphism
rs121917864 (C/T R677W) in a conserved region of TLR2 present only in lepromatous patients,
which suggests a role in susceptibility to this form of the disease [28]. After this, the same
research group published a study demonstrating a role of rs121917864 in innate immune
response activation, specifically the response by monocytes. Patients with the variant 677 W
present a decrease in serum levels of IL-12 after stimulation with cell lysate of M. leprae
compared to the patients with no amino acid substitution confirming that TLR2 is involved
with immune response against M. leprae [26]. Another study also showed the relation of TLR2
with innate immune response studying the polymorphism rs121917864. In this study, the M.
leprae-dependent activation of NK-κB signaling was impaired with 677 W variant in response
to cell wall fractions of M. leprae and M. tuberculosis. These results allow to hypothesize that
this variation in TLR2 may be involved with the poor cellular immune response in leprosy
patients [29]. The profiles of different cytokines are also affected by rs121917864 substitution.
Peripheral blood mononuclear cells (PBMC) from lepromatous leprosy patients carrying this
transition showed a lower level of expression of IL-2, IL-12, IFN-γ, and TNF-α after stimula-
tion withM. leprae. On the other hand, levels of IL-10 increased, while there is no change in IL-
4 production. This alteration in cytokines profiles in lepromatous patients can also be involved
with a low level of cellular immune response in these patients during M. leprae infection [30].
Despite of what was shown in Korean population by Kang and coll. (2001), Malhotra and coll.
(2005) did not identified the rs121917864 substitution in an Indian population. According to
authors, rs121917864 is in fact a variation in a duplicated region 93% homologous located in
exon 3 of TLR2. This duplicated region is a pseudogene [28, 31]. The rs121917864 polymor-
phism was also not identified in Japanese leprosy patients [32]. However, although such
conflicting results may be related to the fact occurring in a duplicated region, these different
results may also be explained by different genetic backgrounds among different populations.
Another important SNP in TLR2 in the context of leprosy is the silent mutation rs3804099 (C/T
N199 N). Santana and coll. (2017) found that the T allele is associated with an increased risk to
leprosy and patients carrying this allele produce a high level of IL-17 and IL-6. In this same
study, an intronic transition of SNP in TLR2 rs7656411 (G3724 T) presented no association with
leprosy in Brazilian population. However, individuals carrying G allele presented high levels
of CXCL10 production [23]. Although no association of rs3804099 (C/T N199 N) with leprosy
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was found, Bochud and coll. (2008) have already demonstrated that T allele has a protective
effect against reversal reaction [33].
In addition to SNPs, microsatellites are important polymorphisms that can be markers of
disease susceptibility, and there are studies trying to identify microsatellites in TLR2 and
investigating their association with leprosy conditions. In an case-control study with leprosy
patients from Ethiopia, a microsatellite upstream to TLR2 start codon containing two variable
nucleotide tandem repeats (VNTR) (CT and TG) is associated with leprosy reversal reaction
which is mainly characterized by a Th1 immune profile [33]. TLRs are able to modulate the
immune response inducing a Th1 or Th2 profile; in this way, changes in these receptors may
lead to a differentiation in immune profile from patients and involve with development of
leprosy reactions. The microsatellite characterized by GT repeats on intron II of TLR2 is
associated with protection against leprosy with 13 repeats being related to resistance. On the
other hand, longer GT repeats are associated with a decrease in TLR2 expression and increase
in IL-10 production being associated with leprosy susceptibility [34].
2.3. Genetic variations in TLR4
TLR4 has as main ligand LPS from Gram-negative bacteria. However, studies have already
demonstrated that TLR4 also recognizes ligands from M. leprae [35, 36]. TLR4 acts through
MyD88-dependent and MyD88-independent (TRIF) signaling [37, 38].
The association of polymorphisms in TLR4 with leprosy susceptibility was investigated in some
studies reinforcing the involvement of this gene in response against leprosy. Bochud and coll.
(2009) identified two polymorphisms rs4986790 (G/A D299G) and rs4986791 (C/T T399I) with
the minor alleles presenting a protective effect against leprosy in an Ethiopian population.
Eventually, these variations may have a role in TLR4-induced effects in immune response against
leprosy [39]. Polymorphism rs4986790 was also investigated in a population from Malawi
revealing borderline association with leprosy. There is a increased frequence of heterozygosity
in control group which is contradictory with another study that demonstrated that heterozygos-
ity of rs4986790 was associated with hyporesponsiveness after LPS inhalation [40, 41]. However,
the Malawi study was corroborated by a family-based and case-control study, in which the AA
genotype was associated with leprosy susceptibility and GA genotype associated with leprosy
protection in an Indian population [42]. Aiming to understand the effect of polymorphisms in
TLR4 signaling, Figueroa and coll. (2012) compared cells of human embryonic kidney 293/CD14/
MD2 complemented with wild-type TLR4 and mutant variants. No differences in TLR4 expres-
sion were identified after induction by LPS. However, the TLR4 signaling was altered since
MyD88 and TRIF recruitment were impaired with TLR4 carrying the rs4986790 polymorphism.
These results were also observed with polymorphism rs4986791, however, in a lesser extent [43].
Changes in non-translated regions of TLR4 gene may also be able to induce changes in immune
profile. The A > G substitution in an intergenic upstream region (rs1927914) andA >G substitution
in an intronic region (rs1927911) were associated with both leprosy per se and leprosy reactions.
Although rs1927911 induces no differences in cytokines and chemokines level of production, the
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allele A of rs1927914 is associated with a higher expression of IL-17 and IL-1β, which is highly
produced in multibacillary leprosy patients [23].
2.4. Genetic variations in toll-interacting protein (TOLLIP)
The activity of TLRs must be under tight regulation to avoid an exacerbated response that
would be harmful to the host. Toll-interacting protein (TOLLIP) is an adaptor protein which
impairs the NF-κB and JNK signaling induced by TLR2 and TLR4, among other signaling
pathways, playing a role in immune response regulation. TOLLIP is able to suppress IRAK-1
activity facilitating IL-1R/TLR-induced cell signaling during inflammation [44, 45]. After TLR2
stimulation, TOLLIP regulates the pro-inflammatory and anti-inflammatory balance by
inhibiting IL-6 and TNF and stimulating IL-10 [46].
In this way, changes in TOLLIP activity may be related to leprosy susceptibility. In a Mexican
population, the possible association of TOLLIP polymorphisms with leprosy susceptibility
was analyzed. The following four polymorphisms were investigated in lepromatous leprosy
patients and control individuals: promoter 526 C > G (rs5743854), silent mutation rs3750920
(C/T P139P), rs5744015 (C/A A222S), and 3’UTR rs3750919 (G/A). However, no association
was identified between the cited polymorphisms and lepromatous leprosy, but a trend of
protective association to lepromatous leprosy was identified in homozygous CC genotype of
rs3750920 [44].
Six haplotype-tagging SNPs were also analyzed regarding association with leprosy in a popu-
lation from Nepal. Among the tested SNPs, the intronic rs3793964 (C/T) exhibited association
with leprosy being the TT genotype associated with leprosy susceptibility. Moreover, TT
genotype and T allele were associated with increased expression of TOLLIP and IL-1Ra in the
skin tissue. The study also demonstrates that TOLLIP induces IL-1Ra in monocytes that inhibit
IL-1R activating helping M. leprae to evade from host immune response in early stages of
leprosy development [47].
3. Genetic variations in nucleotide-binding oligomerization domain-
containing protein 2 (NOD2)
Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) is a family of intra-
cellular PRR that is able to recognize bacterial molecules. Humans have 23 different NLRs that
present two characteristic domains: NOD and leucine-rich repeats (LRRs). The first one is
required for oligomerization, while the second one is required for ligand binding. There are
different subfamilies of NLRs [48]. Some NLRs activate the protease caspase-1, so they act
through inflammasomes leading to pyroptosis. The inflammasome-related NLRs are NLRP1,
NLRP3, NLRP6, NLRP7, NLRP12, NLRC4, and NAIP. However, other components of NLR
family (NOD1, NOD2, NLRP10, NLRX1, NLRC5, and CIITA) act through activation of NF-κB,
mitogen-activated protein kinases (MAPKs), and interferon regulatory factors (IRFs) leading to
innate immune response stimulation [4].
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There are some PAMPs exclusively recognized by NLRs, such as muramyl dipeptide (MDP)
that is a constituent of peptidoglycan cell wall present in Gram-positive and Gram-negative
bacteria [49]. M. leprae, in turn, presents a distinct MDP structure, and some studies have
evidenced the role of NOD2 in recognizing M. leprae through MDP [50]. NOD2-mediated
recognition of MDP from M. leprae induces bacterial killing activating NF-κB signaling cas-
cade, production of IL-32, differentiation of dendritic cells, and autophagy [51–53].
Due to its role in immune response modulation, variations in NOD2 gene is involved with
different inflammatory diseases, such as Crohn’s disease [54], Blau’s syndrome [55], arthritis
[56], and others. In this sense, several studies have investigated the association of NOD2
genetic variants with leprosy susceptibility and leprosy reaction.
In a genome-wide association study from Zhang and coll. (2009) about susceptibility to leprosy
in a Chinese population, variants in six genes of innate immune response were identified as
associated with the disease (CCDC122, C13orf31, NOD2, TNFSF15, HLA-DR, and RIPK2). Specif-
ically, in NOD2 gene, two variants were identified in association with susceptibility to the
disease: rs9302752 (A/G) and rs7194886 (G/A), being the first one with a stronger association
with multibacillary leprosy. The two other evaluated SNPs in NOD2, rs8057341 (A/G) and
rs3135499 (A/C), exhibited no association with leprosy in this study [57]. After this genome-
wide association study, Grant and coll. (2012), in a family-based study, tried to validate in a
Vietnamese population the genetic variants previously associated with leprosy in the Chinese
study. They analyzed SNPs in HLA-DR-DQ, RIPK2, CCDC122-LACC1, and NOD2 in leprosy
patients and control individuals. Four polymorphisms were evaluated in NOD2: rs9302752,
rs7194886, rs8057341, and rs3135499. The G risk allele for the variant rs9302752 was associated
with leprosy, as identified in Chinese population. According to this Vietnamese study, some
variants identified by Zhang and coll. may not directly associated with leprosy risk, but they
are in linkage disequilibrium with another variants, which are the causal ones. This possibility
could explain the divergent results found in different studies [57, 58].
In a subsequent study, Marcinek and coll. (2013) genotyped the variant rs9302752 but now in
an Indian population. However, this variant was not in Hardy-Weinberg equilibrium in this
population. Some other variants in genes involved in signaling pathways mediated by NOD2
were shown to be associated with leprosy in this study. One of them is the haplotype formed
by rs40457 G and rs42490 A in RIPK2 gene that together with NOD2 is responsible for activate
NF-κB signaling. This haplotype gives an increased risk to leprosy in individuals, whereas the
haplotype AA has a protective role. In addition, the minor A allele of rs1873613 polymorphism
in LRRK2 is associated with paucibacillary leprosy progression [59].
Other conflicting results about genetic variants in NOD2 and their relation with leprosy
emerged in a Brazilian study from Marques and coll. (2014) [60]. In this study, authors aimed
to validate the results found in the previous Chinese study regarding SNPs in four genes:
CCDC122-LACC1, NOD2, TNFSF15, and RIPK2 [57]. The A allele of variant rs8057341 in
NOD2 was associated with leprosy resistance in Brazilian population. This result is also
different from that identified in Vietnamese study, in which rs8057341 has no association with
leprosy. Other variants from NOD2, besides rs8057341 A, were related to leprosy protection
being under-transmitted to the affected offspring in Brazilian population: rs2111234 G and
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rs3135499 C [58, 60]. These conflicting results may be, at least partially, related to different
genetic backgrounds among different populations.
The previous study conducted by Zhang and coll. was realized in a Han Chinese population,
which is the main ethnic group from China [57, 61]. A second study was realized in a Chinese
population evaluating the genetic association of NOD2 (C13orf31 and CCDC122) with leprosy
but now in a population from Yi ethnic group that represents a minority group. The following
polymorphisms in NOD2 were investigated: rs9302752, rs7194886, rs8057341, and rs3135499.
Only the SNP rs3135499 was differentially distributed between leprosy patients and healthy
control individuals [62]. This result is different from that found for rs9302752 by Zhang and
coll., Marcinek and coll., and Grant and coll. and rs7194886 and rs8057431 by Zhang and coll.
[57–59].
Even with some discrepant results, the cited studies agree in associate NOD2 with leprosy,
however, with different specific variants. These differences may be due to the influence of
different ethnicities or linkage disequilibrium between different SNPs.
In addition to association with susceptibility to leprosy, variation in NOD2 may be related to
susceptibility to development of leprosy reactions. Leprosy reactions are acute inflammatory
reactions that may occur before leprosy diagnosis, during the treatment or after the treatment.
Some factors are able to initiate these reactions, like intercurrent infections, pregnancy, and
physical and emotional stress, among others [63]. Leprosy reactions are classified into two
main types: type 1—reversal reaction (RR) and type 2—erythema nodosum leprosum (ENL).
RR occurs mainly in earlier stages of treatment but can also occur after the treatment, in
borderline clinical forms. It is characterized by an exacerbated Th1 response. The patient with
RR presents an exacerbation of preexisting lesions, which became edematous and erythema-
tous and may develop ulceration. RR is the leading cause of nerve damage in leprosy and
consequent physical disability [63–65]. ENL, in turn, mainly occurs in lepromatous and bor-
derline lepromatous leprosy and may happen during treatment but is more frequent after the
treatment. Patients present subcutaneous nodules that are painful and erythematous and also
may be ulcerative. In this kind of reaction, immune complexes are related to their initiation,
but cell-mediated immunity also plays a role in ENL. There is an increase in CD4+ T cells, TNF-
α, and IFN-γ [63, 66, 67]. Several studies have already evidenced the possible functional
mechanisms by which NOD2 plays a role during development of leprosy reactions by pro-
inflammatory activities. The stimulation of Th1 and Th2 is one of these mechanisms [68, 69], as
well as negative regulation of TLR2-mediated Th1 response [33, 70, 71].
Some of the previously mentioned polymorphisms in NOD2 (rs7194886, rs9302752, and
rs8057341), besides the additional rs751271 (G/T) and rs2066843 (C/T), were investigated for
their association with leprosy inflammatory reactions in a Brazilian population. The variant
rs751271 is associated with leprosy, being the genotype TT related to faster reaction develop-
ment, whereas the genotype GT and G allele carriers are protection factors against leprosy
reactions. The authors also suggest that rs751271-GT genotype produces lower levels of IL-6 in
patients without reaction, so the hypothesis is that individuals with this genotype present a
better balance in cytokine production which could be related to protection against leprosy
reactions [72].
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Polymorphism rs751271 were already investigated in a Nepal population regarding its associ-
ation with reactive states of leprosy showing no association with type 1 reversal reaction (RR)
neither with erythema nodosum leprosum (ENL). In this study, 32 polymorphisms in NOD2
gene were evaluated. Four out of 32 polymorphisms were associated to leprosy susceptibility
when the allele frequencies were compared between leprosy patients and healthy control:
rs12448797, rs2287195, rs8044354, and rs1477176. When the genotype frequencies were com-
pared, eight SNPs were associated with leprosy: rs2287185, rs8044354, rs8043770, rs13339578,
Table 2. Association studies of genetic polymorphisms in NOD2 and leprosy.
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rs4785225, rs751271, rs12448797, and rs1477176. The variants rs12448797 and rs1477176 are
located in genes adjacent to NOD2, SL1C1, and CYLD, which are regions in linkage disequilib-
rium with NOD2 that may influence the expression of SL1C1 or CYLD and NOD2. Regarding
to RR, five SNPs showed association of their allele frequencies (rs2287195, rs8044354,
rs8043770, rs7194886, and rs1861759), and seven SNPs exhibited association of their genetic
frequencies in a dominant model (rs2287195, rs8044354, rs8043770, rs7194886, rs1861759,
rs4785225, and rs751271). Four SNPs were associated with ENL in an allelic level (rs8044354,
rs17312836, rs1861758 and rs1861759), while seven SNPs at the genotypic level (rs2287195,
rs8044354, rs7194886, rs6500328, rs17312836, rs1861759, and rs18611758) [73].
The association of polymorphisms in NOD2 gene with leprosy reactions highlights the poten-
tial role of this gene in susceptibility and development of RR and ENL. The genetic association
studies between NOD2 and leprosy are summarized in Table 2.
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